Armbrecht U, Reul W, Stockbrügger R W
Marbachtalklinik, Bad Kissingen.
Z Gastroenterol. 1990 Feb;28(2):85-9.
In a placebo controlled trial, the effect of the M1-antagonist telenzepine (3 mg in the morning) and of the dopamine antagonist domperidone (10 mg t.d.s.) was studied on bowel habits, on oro-caecal and on oro-anal transit time. The study was carried out on healthy subjects double-blind, multiple cross-over. The test periods were seven days each interrupted by wash-out periods of seven days. Stool weight, frequency and consistency as well as side-effects were recorded daily. The oro-anal transit time was estimated by evaluating the excretion of orally ingested radiopaque markers. The oro-caecal transit time was studied by means of a hydrogen breath test after a standard meal. The oro-caecal transit time was significantly prolonged during medication with telenzepine, both compared with placebo (p less than 0.05) and with domperidone (p less than 0.01). Bowel habits and the oro-anal transit time remained statistically unchanged during treatment with the active drugs. It is concluded that telenzepine has a dissociate effect on intestinal motility, delaying transit through the upper gastrointestinal tract without affecting the oro-anal transit time.
在一项安慰剂对照试验中，研究了M1拮抗剂替仑西平（早晨服用3毫克）和多巴胺拮抗剂多潘立酮（每日三次，每次10毫克）对排便习惯、口盲肠和口肛转运时间的影响。该研究在健康受试者中进行，采用双盲、多次交叉设计。每个试验期为七天，中间间隔七天的洗脱期。每天记录粪便重量、频率和稠度以及副作用。通过评估口服不透X线标记物的排泄情况来估计口肛转运时间。在标准餐后通过氢呼气试验研究口盲肠转运时间。与安慰剂相比（p<0.05）以及与多潘立酮相比（p<0.01），服用替仑西平期间口盲肠转运时间均显著延长。在使用活性药物治疗期间，排便习惯和口肛转运时间在统计学上保持不变。结论是，替仑西平对肠道运动有解离作用，可延迟上消化道的转运，而不影响口肛转运时间。
